Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study, is to determine the percentage of patients for whom the initial LHRH prescription has been renewed
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LHRH analogues | Drug | 3-or 6-month formulations |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients for whom the initial LHRH prescription (the prescription at the baseline visit) has been renewed at first follow-up visit (same type, same formulation). | First follow-up visit (occurs 3 to 6 months from baseline) |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients for whom the initial LHRH prescription has been renewed at each visit. | Baseline, between 3 to 6 months, 12 months, 18 months and 24 months | |
| Percentage of patients having switched from a 3 months to a 6 months and also 6 months to 3 months formulation at each visit. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients with Prostate cancer locally advanced or metastatic
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ipsen Medical Director | Ipsen | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital A Coruña | A Coruña | 15006 | Spain | |||
| Hospital del Sureste |
Not provided
Not provided
Not provided
Not provided
| Baseline, between 3 to 6 months, 12 months, 18 months and 24 months |
| Percentage of patients starting a 6-month formulation at baseline. | The decision to prescribe a LHRH analogue as a 3- or 6-months formulation will be made prior to and independently from the decision to enroll the subject. This decision should be made in accordance with the usual medical practice of the concerned investigator. | Baseline |
| Reasons leading to a switch from a 3 months to a 6 months formulation (patient) presented as proportion of patients | Baseline, between 3 to 6 months, 12 months, 18 months and 24 months |
| Reasons leading to a switch from a 3 months to a 6 months formulation (physician) presented as proportion of physicians | Baseline, between 3 to 6 months, 12 months, 18 months and 24 months |
| Criteria for choice of formulation at start of hormonal treatment taking into consideration the patient characteristics and his disease status. | Baseline |
| Change of the Quality of Life Questionnaire QLQ-PR25 score compared to baseline and each visit. | Baseline, between 3 to 6 months, 12 months, 18 months and 24 months |
| Correlation between physician and patient satisfaction and the evolution of the biological parameters (Prostate-specific antigen) | Baseline, between 3 to 6 months, 12 months, 18 months and 24 months |
| Percentage of patients for which the initial prescription (the prescription at the baseline visit) of a LHRH analogue (3 or 6 months) has been stopped and later on renewed (intermittent treatment) | Baseline, between 3 to 6 months, 12 months, 18 months and 24 months |
| Arganda |
| 28500 |
| Spain |
| Hospital San Agustín | Avilés | 33401 | Spain |
| Hospital de Txagorritxu | Barakaldo | 48902 | Spain |
| Hospital de Basurto | Bilbao | 48902 | Spain |
| Hospital Gral. Univ. Santa Lucía | Cartagena | 30202 | Spain |
| Hospital Arquitecto Marcide | Ferrol | 15405 | Spain |
| Hospital Univ. de Getafe | Getafe | 28905 | Spain |
| Hospital de Cabueñes | Gijón | 33394 | Spain |
| Hospital Universitario Dr Negrín | Las Palmas de Gran Canaria | 35010 | Spain |
| Hospital de León | León | 37007 | Spain |
| Hospital de la Princesa | Madrid | 28006 | Spain |
| Hospital Univ. La Paz | Madrid | 28046 | Spain |
| Hospital Univ. Infanta Sofía | Madrid | 28703 | Spain |
| Hospital de Torrejón | Madrid | 28850 | Spain |
| Hospital Rey Juan Carlos | Madrid | 28933 | Spain |
| Hospital Comarcal Santiago Apóstol | Miranda de Ebro | 34004 | Spain |
| Hospital Uni. Virgen de la Arrixaca | Murcia | 30120 | Spain |
| Hospital Ntra. Señora del Cristal | Ourense | 36312 | Spain |
| Hospital Son Llàtzer | Palma | 08003 | Spain |
| Hospital Virgen del Camino | Pamplona | 31008 | Spain |
| Hospital de Montecelo | Pontevedra | 36312 | Spain |
| Hospital Univ. de Salamanca | Salamanca | 37007 | Spain |
| Hospital Universitario de Canarias | Santa Cruz de Tenerife | 38320 | Spain |
| Hospital Clínico de Santiago | Santiago de Compostela | 15706 | Spain |
| Hospital Clínico de Valladolid | Valladolid | 47005 | Spain |
| Hospital Álvaro Cunqueiro | Vigo | 36312 | Spain |
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided